FVIII inhibitors: Pathogenesis and avoidance

Blood

Volumn 125, Issue 13, 2015, Pages 2045-2051

  Astermark, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; HLA ANTIGEN CLASS 2; ALLOANTIBODY; BLOOD CLOTTING INHIBITOR;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; ETHNICITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HEMOPHILIA A; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOGENICITY; NONHUMAN; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; RACE; REVIEW; RISK ASSESSMENT; RISK FACTOR; ANCESTRY GROUP; ETHNIC GROUP; ETHNOLOGY; GENETICS; IMMUNOLOGY; METABOLISM;

BLOOD COAGULATION FACTOR INHIBITORS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FACTOR VIII; HEMOPHILIA A; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; ISOANTIBODIES; RISK FACTORS;

EID: 84926155035     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-535328     Document Type: Review

References (74)

1. DasguptaS. NavarreteA.M. BayryJ.et alA role for exposed mannosylations in presentation of human therapeutic self-proteins to CD41 T lymphocytes.Proc Natl Acad Sci USA.2007104218965-8970
2. Delignat S, Repessé Y, Navarrete AM, et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia. 2012;18(2):248-254.
3. Herczenik E, van Haren SD, Wroblewska A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol 2012;129(2):501-509.
4. Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007;109(2):610-612.
5. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000;95(4): 1324-1329.
6. Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP. Blockade of CD40/ CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost. 2001;86(6):1345-1352.
7. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood. 2001;97(9):2750-2757.
8. Hausl C, Ahmad RU, Schwarz HP, et al. Preventing restimulation of memory B cells in hemophilia A: A potential new strategy for the treatment of antibody-dependent immune disorders. Blood. 2004;104(1):115-122.
9. Miao CH, Ye P, Thompson AR, Rawlings DJ, Ochs HD. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood. 2006; 108(1):19-27.
10. Peng B, Ye P, Blazar BR, et al. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood. 2008;112(5):1662-1672.
11. Matzinger P. The danger model: A renewed sense of self. Science. 2002;296(5566):301-305.
12. Pradeu T, Cooper EL. The danger theory: 20 years later. Front Immunol. 2012;3:287.
13. Pordes AG, Baumgartner CK, Allacher P, et al. T cell-independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist. Blood. 2011;118(11):3154-3162.
14. Whelan SF, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013;121(6):1039-1048.
15. Palmer DS, Dudani AK, Drouin J, Ganz PR. Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays. Vox Sang. 1997; 72(3):148-161.
16. Huang CC, Shen MC, Chen JY, Hung MH, Hsu TC, Lin SW. Epitope mapping of factor VIII inhibitor antibodies of Chinese origin. Br J Haematol. 2001;113(4):915-924.
17. Lacroix-Desmazes S, Bayry J, Misra N, et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med. 2002;346(9): 662-667.
18. Lavigne-Lissalde G, Lacroix-Desmazes S, Wootla B, et al. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice. Thromb Haemost. 2007;98(1):138-147.
19. Klintman J, Hillarp A, Berntorp E, Astermark J. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol. 2013;163(3):385-392.
20. Butenas S, Krudysz-Amblo J, Rivard GE, G Mann K. Product-dependent anti-factor VIII antibodies. Haemophilia. 2013;19(4):619-625.
21. Cao O, Loduca PA, Herzog RW. Role of regulatory T cells in tolerance to coagulation factors. J Thromb Haemost. 2009;7(Suppl 1): 88-91.
22. Tang Q, Bluestone JA. The Foxp31 regulatory T cell: A jack of all trades, master of regulation. Nat Immunol. 2008;9(3):239-244.
23. Repessé Y, Peyron I, Dimitrov JD, et al; ABIRISK consortium. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica. 2013; 98(10):1650-1655.
24. Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol. 2007;136(1):12-25.
25. Hausl C, Ahmad RU, Sasgary M, et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood. 2005;106(10):3415-3422.
26. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica. 2000;85(10 Suppl):48-50, discussion 50-51.
27. Carlborg E, Astermark J, Lethagen S, Ljung R, Berntorp E. The Malmö model for immune tolerance induction: impact of previous treatment on outcome. Haemophilia. 2000;6(6):639-642.
28. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD41CD251 regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111(2):715-722.
29. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fcderived peptide "Tregitopes". Blood. 2008;112(8): 3303-3311.
30. Astermark J, Berntorp E, White GC, Kroner BL; MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7(3): 267-272.
31. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost. 1999;82(2):500-504.
32. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12): 2922-2934.
33. Astermark J, Donfield SM, Gomperts ED, et al Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood. 2013;121(8): 1446-1454.
34. Astermark J, Oldenburg J, Escobar M, White GC II, Berntorp E; Malmö International Brother Study study group. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005;90(7):924-931.
35. Eckhardt CL, Menke LA, van Ommen CH, et al. Intensive peri-operative use of factor VIII and the Arg593-.Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost. 2009;7(6): 930-937.
36. Eckhardt CL, van Velzen AS, Peters M, et al INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11): 1954-1962.
37. Pashov AD, Calvez T, Gilardin L, et al. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia. 2014; 20(2):176-184.
38. Pandey GS, Yanover C, Howard TE, Sauna ZE. Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: A computational assessment. PLOS Comput Biol. 2013;9(5): e1003066.
39. Pandey GS, Yanover C, Miller-Jenkins LM, et al PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med. 2013;19(10):1318-1324.
40. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006;107(8): 3167-3172.
41. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009;7(12):2006-2015.
42. Chaves D, Belis ? ario A, Castro G, Santoro M, Rodrigues C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. Int J Immunogenet. 2010;37(2):79-82.
43. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia. 2011;17(4): 641-649.
44. Lu Y, Ding Q, Dai J, Wang H, Wang X. Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A. Thromb Haemost. 2012;107(1):30-36.
45. Pinto P, Ghosh K, Shetty S. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients. Haemophilia. 2012;18(5):794-797.
46. Pergantou H, Varela I, Moraloglou O, et al. Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A. Haemophilia. 2013;19(5):706-710.
47. Fidanc? ID, Z? ulfikar B, Kavakl? K, et al. A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients. Turk J Haematol. 2014;31(1):17-24.
48. Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. Downregulation of CD40 signal and induction of TGF-b by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII. J Pharm Sci. 2012;101(1):48-55.
49. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006;108(12):3739-3745.
50. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost. 2007;5(2):263-265.
51. Pavlova A, Diaz-Lacava A, Zeitler H, et al. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia. 2008;14(2):355-360.
52. Eckhardt CL, Astermark J, Nagelkerke SQ, et al. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A. J Thromb Haemost. 2014;12(8): 1294-1301.
53. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
54. Bouloc A, Bagot M, Delaire S, Bensussan A, Boumsell L. Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production. Eur J Immunol. 2000;30(11):3132-3139.
55. Fernandez I, Zeiser R, Karsunky H, et al. CD101 surface expression discriminates potency among murine FoxP31 regulatory T cells. J Immunol. 2007;179(5):2808-2814.
56. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1998;4(1):68.
57. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360(16):1618-1627.
58. Schwarz J, Astermark J, Menius ED, et al Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia. 2013; 19(1):113-118.
59. Carpenter SL, Michael Soucie J, Sterner S, Presley R; Hemophilia Treatment Center Network (HTCN) Investigators. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia. 2012;18(3): e260-e265.
60. Astermark J, Altisent C, Batorova A, et al European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: A comprehensive review and consensus report. Haemophilia. 2010;16(5):747-766.
61. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood. 1993;81(8): 2180-2186.
62. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost. 1993;69(2): 115-118.
63. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: A systematic review. J Thromb Haemost. 2010; 8(6):1256-1265.
64. Gouw SC, van der Bom JG, Ljung R, et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3): 231-239.
65. Franchini M, Coppola A, Rocino A, et al Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: A 2013 update. Semin Thromb Hemost. 2013;39(7):752-766.
66. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood. 2007;109(11):4648-4654.
67. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: A multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5(7): 1383-1390.
68. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16(2):256-262.
69. Auerswald G, Kurnik K, Blatny J, et al. The EPIC Study: A clinical trial to assess whether early low dose prophylaxis in the absence of immunological danger signals reduces inhibitor incidence in previously untreated patients (PUPs) with hemophilia A. Abstract No. 576. American Society of Hematology Annual Meeting, New Orleans 2013.
70. Gouw SC, van den Berg HM, Fischer K, et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: The RODIN study. Blood. 2013;121(20): 4046-4055.
71. van Velzen AS, Peters M, van der Bom JG, Fijnvandraat K. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: A systematic review. Br J Haematol. 2014;166(4):485-495.
72. Moorhead P, van Velzen A, Sponagle K, et al. Co-administration of factor VIII and dexamethasone prevents anti-factor VIII antibody development in a mouse model of hemophilia A. Abstract No. (OC 56.6) International Society on Thrombosis and Haemostasis Congress 2013, Amsterdam.
73. Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1): 135-142.
74. Garman RD, Munroe K, Richards SM. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin Exp Immunol. 2004;137(3):496-502.